Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Impedimed Limited ( (AU:IPD) ) has shared an announcement.
ImpediMed Limited has released an investor presentation detailing its Q1 FY26 results, which will be delivered to investors and analysts. This announcement is part of the company’s ongoing efforts to maintain transparency with stakeholders and provide insights into its financial performance and strategic direction.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on providing non-invasive medical devices for the assessment of fluid status and body composition. The company primarily targets healthcare providers and patients, offering solutions that aid in the diagnosis and management of conditions such as lymphedema and heart failure.
Average Trading Volume: 1,763,700
Technical Sentiment Signal: Sell
Current Market Cap: A$101.8M
See more data about IPD stock on TipRanks’ Stock Analysis page.